Skip to content

Four doses of PrEP a week may be enough to protect

Detail from iPrEx materials (www.globaliprex.com).

A tale of two trials: how adherence is everything in PrEP

Jared Baeten. Photo by Gus Cairns / aidsmap.com

Second-line treatment failure most often due to poor adherence in low and middle-income countries

For study participants, PrEP was an opportunity to save their relationship

Is a viral load just below 50 copies/ml low enough to ensure the long-term success of HIV therapy?

Social vulnerability associated with lack of satisfaction with health care; doctors need to provide more support

Detectable viral load in patients taking HIV therapy associated with poor control of other chronic health problems

Point-of-care CD4 test improves retention and treatment initiation in Mozambique

Consistent relationship between depression and poor adherence to HIV therapy